Drug affinity complex is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
During protests against ICE operations in Portland, United States, some protesters flew the flag. The flag also saw use during the anti-Trump No Kings 2.0 protests in October 2025, e.g. in Los Angeles, Miami, and Spokane. In Mexico in November 2025, the flag was among various symbols used by a group identifying itself as "Generation Z Mexico", who is against drug violence that claims tens of thousands of Mexican lives each year and the security policies of Mexican president Claudia Sheinbaum. Former Mexican president Vicente Fox wore a T-shirt emblazoned with the symbol while attending the protests. Bulgarians protesting against increases in pension and social security payments in November–December 2025 used the flag. The flag was seen during the "Flamingo Revolution" in Albania. In August 2026, the Straw Hat Pirates' Jolly Roger was spray-painted on the National Monument on Dam Square in Amsterdam, alongside the phrases "Time to wake up!" and "Stop the human trafficking".
The causative agent of yaws is Treponema pallidum pertenue, which is transmissible by direct physical contact between infected people. Yaws is not sexually transmitted, and occurs in tropical, humid environments of Africa, Pacific Islands, Asia and South America. Unlike syphilis, which displays vertical transmission, one strain of T. p. pertenue researched was not vertically transmissible in a guinea pig model, and yaws cannot be spread from mother to offspring. Yaws appears as skin lesions, usually papules, commonly on the lower extremities, but present in other areas such as the arms, trunk and hands. Three stages of yaws disease have been documented: primary yaws which presents as inflamed sores on the lower body, secondary yaws which presents as a variety of skin abnormalities along with bone inflammation, and tertiary yaws, also referred to as latent yaws, which occurs when T. p. pertenue is serologically detected in the host but no clinical signs are displayed until relapse, which often occurs years later. Yaws is treated with antibiotics such as azithromycin and benzathine penicillin-G.
RCO2H + R'2NH → RCO−2 + R'2NH+2 RCO−2 + R'2NH+2 → RC(O)NR'2 + H2O Esters are far superior substrates relative to carboxylic acids. Further "activating" both acid chlorides (Schotten-Baumann reaction) and anhydrides (Lumière–Barbier method) react with amines to give amides:
Sources: en.wikipedia.org
== Health effects == The toxicity of potassium arsenite arises from arsenic’s high affinity for sulfhydryl groups. The formation of these arsenite-sulfur bonds impairs the functionality of certain enzymes such as glutathione reductase, glutathione peroxidases, thioredoxin reductase, and thioredoxin peroxidase. These enzymes are all closely affiliated with the defense of free radicals and the metabolism of pyruvate. Thus, exposure to potassium arsenite and other arsenite containing compounds results in the production of damaging oxygen free radicals and the arrest of cellular metabolism. Additionally, arsenite containing compounds have also been labeled carcinogens. The carcinogenicity of potassium arsenite arises from its ability to inhibit DNA repair and methylation. This impairment of the cellular machinery can lead to cancer because the cells can no longer repair or arrest mutations and a tumor results. All of these conditions exhibit the hazardous nature of potassium arsenite and other arsenite containing compounds. This is evidenced by a LD50 of 14 mg/kg for rats and a TDL of 74 mg/kg for humans.
== Structure == Now known as a continuous organ the mesentery can be divided into two sections, a mesenteric region or domain containing the abdominal digestive components, and a nonmesenteric region containing the urogenital system, musculoskeletal system, and the great vessels. This recognises that the mesenteric digestive organs are all linked. The mesentery of the small intestine arises from the root of the mesentery (or mesenteric root) and is the part connected with the structures in front of the vertebral column. The root is narrow, about 15 cm long, 20 cm in width, and is directed obliquely from the duodenojejunal flexure at the left side of the second lumbar vertebra to the right sacroiliac joint. The root of the mesentery extends from the duodenojejunal flexure to the ileocaecal junction. This section of the small intestine is located centrally in the abdominal cavity and lies behind the transverse colon and the greater omentum. The mesentery becomes attached to the colon at the gastrointestinal margin and continues as the several regions of the mesocolon. The parts of the mesocolon take their names from the part of the colon to which they attach. These are the transverse mesocolon attaching to the transverse colon, the sigmoid mesocolon attaching to the sigmoid colon, the mesoappendix attaching to the appendix, and the mesorectum attaching to the upper third of the rectum. The mesocolon regions were traditionally taught to be separate sections with separate insertions into the posterior abdominal wall.
MOF-177, a MOF designed for CO2 capture, has a heat capacity of 0.5 J/(g⋅K) at ambient temperature. The companies Svante is commercialising CALF-20 for CO2 capture and Captivate Technology is using MUF-16.
Sources: en.wikipedia.org
A depot injection, also known as a long-acting injectable (LAI), is a term for an injection formulation of a medication which releases slowly over time to permit less frequent administration of a medication. They are designed to increase medication adherence and consistency, especially in patients who commonly forget to take their medicine. Depot injections can be created by modifying the drug molecule itself, as in the case of prodrugs, or by modifying the way it is administered, as in the case of oil/lipid suspensions. Depot injections can have a duration of action of one month or greater and are available for many types of drugs, including antipsychotics and hormones.
Hyperphagia or polyphagia is common within Alström populations and has been shown to contribute to weight gain. Moderate to severe hypertriglyceridemia occurs in most individuals. Almost all individuals with AS experience insulin resistance and/or hyperinsulinemia to some degree. Therefore, type 2 diabetes mellitus often results as early as 5 years of age with a median onset of 16 years. Non-alcoholic fatty liver disease is common in AS. This often progresses to non-alcoholic steatohepatitis. Upper and lower respiratory tract infections in childhood, which decrease during adulthood. Bronchitis, pneumonia, and sinusitis have also been reported. Increased susceptibility to hypoxemia during or after surgery. Chronic obstructive pulmonary disease, interstitial lung disease, or acute respiratory distress syndrome is also seen in some older patients. Chronic kidney disease is common in some cases that can lead to end-stage renal disease/kidney failure as early as mid-to late teens. Less than half of individuals experience dysuria. Epigastric pain, nausea, and gastroesophageal reflux disease are common. Delays in gross and fine motor skills, learning disabilities, and mixed receptive-expressive language delays are common. Cognitive impairment, however, is very rare. Delays in early, developmental milestones in 50% of cases, learning disabilities in about 30% of cases. Seizures and hyporeflexia have been reported but are less common (20% of individuals).
=== Graphene === Layering graphene on top of gold has been shown to improve SPR sensor performance. Its high electrical conductivity increases the sensitivity of detection. The large surface area of graphene also facilitates the immobilization of biomolecules while its low refractive index minimizes its interference. Enhancing SPR sensitivity by incorporating graphene with other materials expands the potential of SPR sensors, making them practical in a broader range of applications. For instance, the enhanced sensitivity of graphene can be used in conjunction with a silver SPR sensor, providing a cost-effective alternative for measuring glucose levels in urine. Graphene has also been shown to improve the resistance of SPR sensors to high-temperature annealing up to 500 °C.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.